Back to Search
Start Over
Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
- Source :
- Cancer Science. 113:796-801
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Identifying molecular features is an essential component of the management and targeted therapy of brain metastases (BMs). The molecular features are different between primary lung cancers and BMs of lung cancer. Here we report the DNA and RNA mutational profiles of 43 pathological samples of BMs. In addition to previously reported mutational events associated with targeted therapy, PTPRZ1-MET, which was previously exclusively identified in glioma, was present in two cases of BMs of lung cancer. Furthermore, MET exon 14 skipping may be more common (6/37 cases) in BMs of lung cancer than the frequency previously reported in lung cancer. These findings highlight the clinical significance of targeted DNA plus RNA sequencing for BMs and suggest PTPRZ1-MET and MET exon 14 skipping as critical molecular events that may serve as targets of targeted therapy in BMs.
- Subjects :
- Adult
Male
Cancer Research
Lung Neoplasms
Oncogene Proteins, Fusion
medicine.medical_treatment
education
Targeted therapy
Exon
Glioma
medicine
Humans
Oncogene Fusion
Clinical significance
Lung cancer
Aged
Lung
Brain Neoplasms
Receptor-Like Protein Tyrosine Phosphatases, Class 5
business.industry
digestive, oral, and skin physiology
RNA
Exons
General Medicine
Middle Aged
Proto-Oncogene Proteins c-met
medicine.disease
stomatognathic diseases
medicine.anatomical_structure
Oncology
PTPRZ1
Mutation
Cancer research
Female
business
Subjects
Details
- ISSN :
- 13497006 and 13479032
- Volume :
- 113
- Database :
- OpenAIRE
- Journal :
- Cancer Science
- Accession number :
- edsair.doi.dedup.....441c096e4e628f88a777ee4ba845ac18